We hereby Submit Annual Report of FY 2025-26.

Exporter & Trader of Speciality Medicines Date: 03/09/2026 BSE Limited. PJ Towers, Dalal Street, Mumbai – 400001 Sub: Submission of Annual Report for the Financial Year 2025-26 Reference: Speciality Medicines Limited (Id: SPML; Code: 544738) This is with reference to captioned subject and pursuant to Regulation 34(1) of Securities Exchange Board of India (Listing Obligations and Disclosures requirements) Regulations, 2015, we hereby enclosed herewith Annual Report for the financial year 2025-26. Request you to please take the same on your records. Kindly take the same on your record and oblige us. Thanking you, Yours Faithfully, For, SPECIALITY MEDICINES LIMITED (Formerly Known as Speciality Medicines Private Limited) SUMIT GOYANI Whole-Time Director DIN: 07885780 Place: Mumbai SPECIALITY MEDICINES LIMITED (Formerly Known as Speciality Medicines Private Limited) CIN: L85300GJ2021PLC120022 Corp. Office : Unit 27, Ground Floor, Andheri Sainath Premises Co Soc, 20 Mahakali Caves Road, Andheri (East), Mumbai, Maharashtra, India, 400093 Regd. Office : 913, One World West, S. No. 396, FP 119, Village- Vejalpur, Ahmedabad 380051, Gujarat, India +91 99242 03751 / 99242 43751 info@specialitymedicine.com www.specialitymedicine.com #29AA58 ANNUAL REPORT FY 2025-2026 INSIDE THIS REPORT SPECIALITY MEDICINES LIMITED (Formerly known as Speciality Medicines Private Limited) CIN: L85300GJ2021PLC120022 Sr. No. Particulars Page 1. Corporate Information 1 2. Board of Director’s Report 3 Annexure to the Board of Director’s Report Annexure – A – Annual Report on Corporate Social Responsibility (CSR) Activities For The 19 Financial Year 2025-26 Annexure – B – Form No. AOC-2 (Particulars of Contracts / Arrangements Made With 22 Related Parties) Annexure – C – Particulars Of Employees 23 Annexure – D – Form No. MR-3 (Secretarial Audit Report For The Financial Year Ended 24 March 31, 2026) Management Discussion And Analysis Report 28 3. Financial Section (Standalone) Independent Auditor’s Report 35 Statement of Balance sheet 44 Statement of Profit & Loss Account 45 Statement of Cash Flow 46 Notes forming part of Financial Statement 48 4. Notice of Annual General Meeting 73 CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS NOTICE OF AGM CORPORATE INFORMATION SPECIALITY MEDICINES LIMITED (Formerly known as Speciality Medicines Private Limited) CIN: L85300GJ2021PLC120022 BOARD OF DIRECTORS Names Designation Category Mr. Parthkumar Goyani Chairman & Managing Director Promoter Executive Mr. Sumit Goyani Whole-Time Director Promoter Executive Mr. Bhaveshkumar Savani Non-Executive Director Non-Promoter Non-Executive Mr. Chandresh Unagar Independent Director Non-Promoter Non-Executive Mrs. Archana Bhayani Independent Director Non-Promoter Non-Executive AUDIT COMMITTEE Names Designation Category Mr. Chandresh M Unagar Chairperson Non-Promoter Non-Executive Mrs. Archana Bhayani Member Non-Promoter Non-Executive Mr. Parthkumar Goyani Member Promoter Executive STAKEHOLDERS’ RELATIONSHIP COMMITTEE Names Designation Category Mr. Chandresh M Unagar Chairperson Non-Promoter Non-Executive Mrs. Archana Bhayani Member Non-Promoter Non-Executive Mr. Parthkumar Goyani Member Promoter Executive NOMINATION AND REMUNERATION COMMITTEE Names Designation Category Mr. Chandresh M Unagar Chairperson Non-Promoter Non-Executive Mrs. Archana Bhayani Member Non-Promoter Non-Executive Mr. Bhaveshkumar Savani Member Promoter Non-Executive CORPORATE SOCIAL RESPONSIBILITY COMMITTEE Names Designation Category Mr. Parthkumar Goyani Chairperson Promoter Executive Mr. Sumit Goyani Member Non-Promoter Non-Executive Mrs. Archana Bhayani Member Promoter Executive KEY MANAGERIAL PERSONNEL Names Designation Mr. Kalpesh Pipaliya Chief Financial Officer Ms. Anita Kumawat Company Secretary & Compliance Officer SPECIALITY MEDICINES LIMITED | 1 CORPORATE INFORMATION SPECIALITY MEDICINES LIMITED (Formerly known as Speciality Medicines Private Limited) CIN: L85300GJ2021PLC120022 REGISTERED OFFICE 913, One World West, S. No. 396, FP 119, Village- Vejalpur, Ahmadabad City, Ahmedabad, Gujarat, India, 380051. Website: www.specialitymedicine.com CORPORATE OFFICE Unit 27, Ground Floor, Andheri Sainath Premises Co Soc, 20 Mahakali Caves Road, Andheri (East), Mumbai, Maharashtra, India, 400093 Tel No.: +91 22 4604 5344; Email: investors.grievances@specialitymedicine.com REGISTRAR & SHARE TRANSFER AGENT SKYLINE FINANCIAL SERVICES PRIVATE LIMITED D-153A, 1st Floor, Phase-I, Okhla Industrial Area, Delhi – 110020, India Tel No.: +91 11 4045 0193-97; Email: grievances@skylinerta.com STATUTORY AUDITOR M/s. A K Ostwal & Co., Chartered Accountants, 517, Jeevandeep Complex, Nr. Nirmal Hospital, Ring Road, Surat – 395002, Gujarat, India. SECRETARIAL AUDITOR Hardik Jetani & Associates, Practicing Company Secretaries, 317, Vishala Supreme, S P Ring Road, Nikol, Ahmedabad380009, Gujarat, India INTERNAL AUDITOR Rahul Mistri and Co., Chartered Accountants, 401, White House, Sector-11, Gandhinagar-382010, India BANKERS Kotak Mahindra Bank Limited ANNUAL REPORT 2025-26 | 2 CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS NOTICE OF AGM BOARD OF DIRECTOR’S REPORT Dear Shareholders, countries all over the worlds. Our mission is to enhance The Board of Directors hereby submits the report of the patient care by supplying high-quality, innovative business and operations of “Speciality Medicines Limited medicines that address unmet medical needs. With a strong commitment to excellence, we aim to make a (“the Company”), along with the audited financial statements, for the financial year ended March 31, 2026. positive impact on the lives of patients worldwide. CORPORATE OVERVIEW Our Company is majorly engrossed in the Specialty pharmaceuticals business involving marketing, trading Speciality Medicines Limited was originally incorporated and distribution of wide range of Specialty as “Speciality Medicines Private Limited” as a Private pharmaceuticals finished formulations and products. Limited Company, under the provisions of the Depending upon business requirements, we procured Companies Act, 2013. Later on, pursuant to a special the products from existing manufacturers based in India. resolution passed by our Shareholders in the Extra- Ordinary General Meeting held on April 04, 2024, our Our Company is currently in process of establishing a Company was converted from a private limited company Research and Development (R&D) Center to manage to public limited company and consequently, the name R&D and formulation processes internally. This new R&D center will be equipped with modern laboratories, of our Company was changed from “Speciality pilot-scale manufacturing units, stability chambers, and Medicines Private Limited” to “Speciality Medicines Limited”. advanced analytical instruments such as HPLC, GC and other equipment required for pre-formulation, To raise equity capital from the public, the Company formulation development, analytical method validation, approached BSE Limited in the year 2025. During the stability testing and scale-up processes in compliance same financial year, the Company received approval with Good Laboratory Practices. It will enable us to from BSE Limited to undertake its Initial Public Offering undertake pre-formulation studies, formulation (IPO) and list its equity shares on the SME Platform of development for solid orals, injectables, ophthalmic and BSE Limited. Subsequently, the Company successfully nasal preparations, analytical method development and completed its IPO and its equity shares were listed on validation, stability testing as per ICH (International the SME Platform of BSE Limited on March 30, 2026. Council for Harmonisation) guidelines, and scale- Our company is engaged in marketing & distribution of up/technology transfer activities in compliance with finished formulations of Specialty pharmaceuticals - Good Laboratory Practices (GLP). The centre is high-cost oral or injectable medications use [Showing first 8,000 characters — download PDF for full document]